Study Identifies New Treatment Path for Glioblastoma
Duke-NUS Medical School published research on a new brain-penetrant compound, ETC-501, which may enhance glioblastoma cancer treatment.
Researchers at Duke-NUS Medical School have identified and characterized a new compound, ETC-501, which acts as a brain-penetrant MNK kinase inhibitor. Published in Cancer Res, the study details how ETC-501 can potentiate temozolomide (TMZ)-induced cellular senescence and sensitize glioblastoma cells to senolytic therapy.
The research addresses glioblastoma, an aggressive form of brain cancer that is challenging to treat due to the blood-brain barrier. As a brain-penetrant compound, ETC-501 can cross this barrier and directly affect cancer cells. The compound functions by inhibiting MNK kinase, a protein involved in cell growth and survival.
Findings suggest that ETC-501, in combination with TMZ, could offer improved therapeutic outcomes. It makes cancer cells more susceptible to senolytic therapy, a treatment approach targeting senescent or damaged cells. This dual action presents new avenues for treating glioblastoma patients.
The study was authored by researchers at Duke-NUS and published in Cancer Research on January 22, 2026. The work provides new insights into glioblastoma research and the development of potential novel therapies.